Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692782 · ClinicalTrials.gov registry record · Phase 2
Adult Attention Deficit Hyperactivity Disorder
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT01692782 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 341 participants.
The verdict
NCT01692782, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
Interventions
- DRUG Placebo
- DRUG SEP-225289
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692782
The ClinicalTrials.gov registry entry for NCT01692782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01692782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692782 about?
NCT01692782 is a clinical study titled "Adult Attention Deficit Hyperactivity Disorder". A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
What is the current status of trial NCT01692782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2012-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01692782?
The interventions under investigation include: Placebo (DRUG), SEP-225289 (DRUG).
Who is sponsoring clinical trial NCT01692782?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.